Skip to content
Abierto
Menu

Justification

Sole Source - TheraSphere Y90 Treatments

FA442725C0003

Department of the Air Force, FA4427 60 Cons LGC. Pharmaceutical Preparation Manufacturing.

View on SAM.govMarkdown

Awarded

Boston Scientific Corp.

$720,000.00 obligated so far on USAspending, December 6, 2024, contract FA442725C0003

Description

As published on SAM.gov.

The 60th Contracting Squadron at Travis Air Force Base, CA 94535 has awarded a sole-source contract to Boston Scientific Corp. under the authority of FAR 6.305. The contract is for the FDA-approved TheraSphere product, a liver cancer therapy consisting of small glass microspheres containing radioactive Yttrium-90 (Y90). TheraSphere is the only FDA-approved treatment for primary liver cancer and is indicated for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC). The contract was awarded to support the treatment of liver cancer patients within the Regional Health Command Central (RHC-C).

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Boston Scientific Corp.
UEI
YWDHHW3DLNQ1
CAGE
1FKE6
Vendor location
Marlborough, MA
Contract
FA442725C0003, definitive contract
Obligated
$720,000.00, potential $3,960,000
Actions
1 between December 5, 2024 and December 5, 2024
Competition
Not Competed, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Therasphere Y90 Treatments.
Match
award number FA442725C0003 equals the contract number; same awarding office FA4427 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. December 5, 2024

    Justification

    SAM.gov, notice 475133209de240b0b3b176eb73be08f7

Points of contact

Also open from this buyer